Combination therapy vs. standard chemo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced stomach or gastroesophageal junction cancer that is HER2-negative and cannot be removed with surgery.
- You have not had any chemotherapy or other cancer treatment for advanced disease, though prior treatment for early-stage cancer is allowed if it ended at least 6 months ago.
- Your cancer must be measurable on scans.
- You are in good enough health to be up and about (ECOG score 0–1) and expected to live more than 3 months.
- Your kidney function is adequate (creatinine clearance at least 60 mL/min) and your blood counts and liver function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a combination of two drugs—becotatugvedotin (which targets EGFR on cancer cells) and pucotenlimab (an immunotherapy that helps the immune system fight cancer)—for people with advanced stomach or GEJ cancer that is EGFR-positive and has progressed after one prior treatment. It aims to see if this combo can shrink tumors or slow the cancer's growth.
Hear when a new Gastric (Stomach) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.